title: Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the efficacy of a protein-based pattern in serum previously determined by MALDI-TOF-MS (Matrix Assisted Laser Desorption Ionization-Time of Flight) and considered potentially useful for prediction of clinical outcome of EGFR (epidermal growth factor receptor) TKIs (tyrosine kinase inhibitors) treated patients.
  
  
  METHODS
  We generated SELDI-TOF (Surface Enhanced Laser Desorption Ionization-Time of Flight) spectra in sera of 11 advanced NSCLC treated with Gefitinib. We detected the clusters with m/z 5843, 11445, 11529, 11685, 11759 and 11903 which were previously reported to be potential predictors of response to Gefitinib treatment.
  
  
  RESULTS
  Four cluster peaks with m/z 5843, 11445, 11529, 11685 corresponded to SAA (serum amyloid A) protein on the basis on their calculated molecular weight, peptide fingerprinting and antibodies recognition.
  
  
  CONCLUSIONS
  We confirm that several proteins already reported were isoforms of SAA but further studies are in development in order to evaluate the predictive value of such algorithm.
authors.affiliation: IRCCS National Cancer Centre Giovanni Paolo II, Department of Experimental Oncology, Bari, Italy. vmgarrisi@libero.it
authors.forename: V M
authors.initials: VM
authors.lastname: Garrisi
authors.forename: I
authors.initials: I
authors.lastname: Bongarzone
authors.forename: A
authors.initials: A
authors.lastname: Mangia
authors.forename: M
authors.initials: M
authors.lastname: Cremona
authors.forename: M
authors.initials: M
authors.lastname: De Bortoli
authors.forename: E
authors.initials: E
authors.lastname: Vaghi
authors.forename: D
authors.initials: D
authors.lastname: Galetta
authors.forename: U
authors.initials: U
authors.lastname: Pastorino
authors.forename: M
authors.initials: M
authors.lastname: Quaranta
authors.forename: I
authors.initials: I
authors.lastname: Abbate
authors.forename: A
authors.initials: A
authors.lastname: Paradiso
mesh_terms: D000368:Aged; D000465:Algorithms; D001798:Blood Proteins / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D016022:Case-Control Studies; D018450:Disease Progression; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D001798:Blood Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077156:Gefitinib